:

Franco Locatelli1, Marina Cavazzana2, Haydar Frangoul3

  • 1Department of Pediatric Haematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, 00165 Rome, Italy; Catholic University of the Sacred Heart, 00168 Rome, Italy.

概括

基因疗法为输血依赖的β-thalassemia和状细胞疾病 (SCD) 提供了潜在的一次性治疗方法. 临床试验正在评估这些遗传性血液疾病的lentiviral载体和基因编辑工具,如CRISPR-Cas9.